

 a surfactant selected from the group consisting of tocoferol and tocoferol covalently linked to a water-soluble polymer;

wherein the composition forms a micelle].

4. (Amended) The fluid pharmaceutical composition of claim 1 wherein the podophyllotoxin is etoposide.

5. (Amended) The fluid pharmaceutical composition of claim 1 wherein the surfactant is tocoferol.

7. (Amended) The fluid pharmaceutical composition of claim [6] 1 wherein the water-soluble polymer is poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers polyacrylamides, polyglycerols, polyvinylalcohols, polyvinylpyrrolidones, polyvinylpyridine N-oxides, copolymers of vinylpyridine N-oxide and vinylpyridine, polyoxazolines, polyacroylmorpholines or derivatives thereof.

8. (Amended) The fluid pharmaceutical composition of claim [6] 1 wherein the water-soluble polymer is a polypeptide or derivative thereof.

9. (Amended) The fluid pharmaceutical composition of claim [6] 1 wherein the water-soluble polymer further comprises a second hydrophobic group [other than] in addition to tocoferol.

10. (Amended) The fluid pharmaceutical composition of claim 1 wherein the surfactant is d- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate [(TPGS)] or a derivative thereof.

11. (Amended) The fluid pharmaceutical composition of claim 10 wherein the [(TPGS)] d- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate is present at a concentration from about 0.02 wt % to about 20 wt %.

12. (Amended) The fluid pharmaceutical composition of claim 10 wherein the [(TPGS)] d- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate is present at a concentration from about 0.02 wt % to about 10 wt %.

13. (Amended) The fluid pharmaceutical composition of claim 10 wherein the [(TPGS)] d- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate is present at a concentration from about 4 wt % to about 10 wt %.

14. (Amended) The fluid pharmaceutical composition of claim 1 further comprising a targeting molecule.

15. (Amended) The fluid pharmaceutical composition of claim 14 wherein the targeting molecule comprises a targeting moiety and a lipophilic moiety.

16. (Amended) The fluid pharmaceutical composition of claim 15 wherein the targeting moiety is an antibody, hormone, carbohydrate, drug, cytokine, or interleukin.

17. (Amended) The fluid pharmaceutical composition of claim 15 wherein the targeting moiety is a peptide.

18. (Amended) A method of treating an animal comprising administering to the animal a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising:

a podophyllotoxin[, an analog thereof or derivative thereof] selected from the group consisting of etoposide and teniposide, and

a surfactant selected from the group consisting of tocoferol and tocoferol covalently linked to a water-soluble polymer[;

wherein the composition forms a micelle].

19. (Amended) The method of claim 18 wherein the surfactant is TPGS or a derivative thereof.

20. (Amended) A method of delivering a podophyllotoxin[, an analog thereof or derivative thereof] selected from the group consisting of etoposide and teniposide to a cell comprising administering to the cell a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising:

a podophyllotoxin[, an analog thereof or derivative thereof] selected from the group consisting of etoposide and teniposide; and

a surfactant selected from the group consisting of tocoferol and tocoferol covalently linked to a water-soluble polymer[.;

wherein the composition forms a micelle].

21. (Amended) A method of inhibiting cancer comprising administering to an animal having cancer a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising:

a podophyllotoxin[, an analog thereof or derivative thereof] selected from the group consisting of etoposide and teniposide; and

a surfactant selected from the group consisting of tocoferol and tocoferol covalently linked to a water-soluble polymer[;

wherein the composition forms a micelle].

Add new claims 22-24 reading as follows: